Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Anti-inflammatory activity of polyamide dendrimers bearing bile acid termini synthesized via SPAAC

Full text
Garzon-Porras, Ana M. [1, 2] ; Bertuzzi, Diego L. [1] ; Lucas, Kurt [2] ; Ornelas, Catia [1]
Total Authors: 4
[1] Univ Estadual Campinas, Inst Chem, UNICAMP, BR-13083970 Campinas, SP - Brazil
[2] Max Planck Inst Chem, Hahn Meitner Weg 1, D-55128 Mainz - Germany
Total Affiliations: 2
Document type: Journal article
Web of Science Citations: 0

Inflammation is a general pathomechanism associated with numerous diseases of global impact such as many cancers, metabolic disorders, and neurodegenerative and autoimmune diseases. The development of drugs that can treat chronic inflammation, in an effective way and that are well tolerated by the patients, is an active research area that pursues the treatment for hundreds of diseases. Dendrimers recently appeared as a convenient starting point for the design of anti-inflammatory drugs due to its nanosize, well-defined branched structure, multivalency, and versatility. In this work, polyamide dendrimers with 1 \& x2794; 3 connectivity were synthesized and functionalized with three types of bile acids (BAs): cholic acid (CA), ursodeoxycholic acid (UDCA), and chenodeoxycholic acid (CDCA). Functionalization was carried out through strain-promoted alkyne-azide cycloaddition (SPAAC) between an azide dendrimer and cyclooctyne derivatives of bile acids. The cell viability and the anti-inflammatory potential of the bile acid dendrimers were evaluated in vitro and compared with those of the pure BAs. The bile acid dendrimers and pure BAs did not show significant cytotoxicity at the concentrations tested (0.78-5.00 x 10(4) nM) against THP-1 cells. Chenodeoxycholic acid (CDCA) and the corresponding dendrimer dendri-(CDCA)(18) (polyamide dendrimer bearing 18 CDCA moieties) presented the highest anti-inflammatory activity, showing LPS-induced IL-8 release inhibition of 45.3% at 0.78 nM CDCA and 35.5% at 0.43 nM dendri-(CDCA)(18). (AU)

FAPESP's process: 18/02093-0 - Development of new nanomaterials for nanomedicine applications
Grantee:Cátia Cristina Capêlo Ornelas Megiatto
Support Opportunities: Regular Research Grants
FAPESP's process: 15/04929-0 - Development of biosensors for instantaneous detection of proteins and cancer cells, for application on on-site biopsy
Grantee:Diego Luan Bertuzzi
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)